Trial Profile
Phase II, Randomized, Placebo-controlled, Double-blind, Parallel-group Study of KWA-0711 Administered Orally for 4 Weeks to Evaluate Its Efficacy and Safety, and to Determine Its Optimal Dose in Patients With Chronic Constipation (CC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Mizagliflozin (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 15 Apr 2016 Status changed from recruiting to completed.
- 05 Nov 2014 New trial record